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Abstract The objective of this study is to investigate the
impact of control of blood glucose level during treatment
of sudden deafness. A retrospective study was performed
involving 197 patients from January, 2011 to September,
2015. All patients were administrated prednisolone
(Pharmaprednisolone tab, 5 mg/T; KoreaPharma) p.o
under the following regimen: 60 mg/day for 4 days,
40 mg/day for 2 days, 30 mg/day for 1 day, 20 mg/day for
1 day, and 10 mg/day for 2 days. During treatment, pure
tone audiometry and blood glucose level were investigated
for each patient and the results were statistically analyzed.
Mean hearing improvement was 19.2 dB for the non-dia-
betes group and 24.8 dB for the diabetes group. The greater
improvement for diabetics was not statistically significant
(p = 0.146). Hearing improvement was 25.1 dB for sub-
jects with mean blood glucose\200 mg/dl and 24.6 dB for
subjects with mean blood glucose[200 mg/dl; the differ-
ence was not statistically significant (p = 0.267). Mean
blood glucose level was 200.8 mg/dl for subjects with
hearing improvement[20 dB and 181.8 mg/dl for subjects
with hearing improvement\20 dB; the difference was not
statistically significant (p = 0.286). Control of blood glu-
cose level during treatment of sudden deafness does not
have a direct effect on prognosis.
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Introduction
Sudden deafness is defined as the sudden development of
unilateral or bilateral sensorineural hearing loss. Virus
infection and blood circulation disorder are considered as
major etiologies, but the exact cause still remains contro-
versial [1]. Mechanisms involved in the induction of
hearing loss by different viruses vary greatly, raging from
damage to direct inner ear structures, to induction of host
immune-mediated damage. Currently, steroid use is an
effective treatment in treating patients with sudden deaf-
ness [2]. However, hyperglycemia in patients with diabetes
remains as an obstacle in treating sudden deafness. Studies
have investigated the prognosis of sudden deafness with
diabetes as a factor [1, 2], but prognosis according to
hyperglycemia during steroid treatment has not yet been
studied. The purpose of our study was to suggest mecha-
nism that blood glucose level during steroid treatment
could affect improvement in sudden deafness patients.
Materials and methods
Subjects
The retrospective study involved 197 patients diagnosed
with sudden deafness with unknown origin in our hospital
from January, 2011 to September, 2015. Fifty-seven
patients with type 2 diabetes were included and a thorough
physical examination and systemic review were conducted
for each patient. All diabetic patients had been receiving
oral hypoglycemic medication such as metformin (Diabex
Tab, 500 mg/T; Daewoong) and glimepiride (Amaryl
Tab, 2 mg/T; Handok) were on regular follow-up for their
blood glucose levels. The initial glucose level upon
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admission was fairly under control which was 143 mg/dl.
For the diabetes group, they were divided into 2 groups;
group I as glucose level [200 mg/dl, and group II as
\200 mg/dl. The reason for this division was to investigate
whether glucose levels during treatment had effect on
prognosis. Also, the diabetes group was again categorized
into group A as patients with hearing improvement
[20 dB, and group B with hearing improvement\20 dB.
This was to investigate whether patients who showed
improvement in sudden deafness also had well-controlled
glucose level during treatment.
Patients who commenced treatment within 7 days of
onset were included but those who had vertigo, tinnitus
were excluded from the study. Also, routine blood tests and
serological viral studies were performed to exclude viral,
inflammatory, traumatic origin. This study was determined
to be exempt from review by the institutional review board
at our institution.
Treatment method
All patients were administrated prednisolone (Pharmapred-
nisolone tab, 5 mg/T; KoreaPharma) p.o under the fol-
lowing regimen: 60 mg/day for 4 days, 40 mg/day for
2 days, 30 mg/day for 1 day, 20 mg/day for 1 day, and
10 mg/day for 2 days. Control of blood glucose was done
through self-medication for each patient. For control of
hyperglycemia, Insulin aspart (Novorapid, 100 IU/ml;
Novo Nordisk) was administered subcutaneously. If glucose
level was greater than 200 mg/dl, 4 units of Insulin aspart
was administered upon consultation with internal medicine
doctors. For every 50 mg/dl increase in glucose level, 1 unit
of Insulin aspart was increased. Blood glucose stick test was
performed 1 h after insulin injection to follow up blood
glucose levels.
Audiometry and blood glucose level examination
Initial pure tone audiometry was performed before
treatment and once every 2 days during treatment. Pure
tone audiometry was performed 1 month after treatment
for final evaluation. Audiometry was evaluated using
four frequencies (0.5, 1, 2, and 3 kHz). Patients had
their meal at 7 am, 12 pm, and 6 pm. Glucose stick test
was performed four times daily (7 am, 10 am, 4 pm,
and 9 pm) to measure fasting glucose. Two-hour pre-
prandial glucose and 3-h post-prandial glucose tests
were done. Although Hb A1c (glycosylated hemoglo-
bin) is known as a good indicator of long term glucose
control, glucose stick test was used in this study to
evaluate the four specific periods each day after steroid
was administered.
Statistical analysis
All statistical evaluations were performed using SPSS
version 12.0 (SPSS, Chicago, IL, USA) and p values\0.05
were considered significant. Comparison of hearing
improvement between the diabetes group and non-diabetes
group was done using Mann–Whitney U test and evalua-
tion of hearing improvement according to control of blood
glucose level was done using the Kruskal–Wallis test.
Results
Objective hearing improvement in diabetes
and non-diabetes patients
The 197 patients included 140 non-diabetes patients inwhich
63weremale, 77 were female, andmean age was 46.8 years.
For the non-diabetes group, the average initial pure tone
audiometry was 60.3 dB and final audiometry performed
1 month after treatment was 41.2 dB. There were 57 dia-
betes patients, comprising 34 males, 23 females; their mean
age was 57.4 years. Average initial pure tone audiometry for
the diabetes group was 72.1 dB and final audiometry was
47.3 dB (Fig. 1). By defining hearing recovery as improve-
ment in pure tone audiometry[10 dB, 76 patients (54.3%) in
the non-diabetes group showed hearing recovery and 37
patients (64.9%) in the diabetes group showed hearing
recovery. Hearing improvement was measured from the
difference in the initial and final pure tone audiometry.
Hearing improvement was 19.2 dB for the non-diabetes
group and 24.8 dB for the diabetes group; the greater
improvement for the diabetes group was not statistically
significant (p = 0.146) (Table 1).
Hearing improvement according to control of blood
glucose level
Mean glucose level was obtained by the average of the glu-
cose stick test result during treatment, and glucose level
[200 mg/dl was categorized as group I, which included 24
patients, and\200 mg/dl as group II, which included 33
patients. Hearing improvement according to control of blood
glucose level was 25.1 dB for group I and 24.6 dB for group
II, but it was not statistically significant (p = 0.267) (Fig. 2).
Comparison of blood glucose level according
to hearing improvement
Patients with hearing improvement[20 dB in pure tone
audiometry was categorized as group A, which included 30
patients, and \20 dB as group B, which included 27
patients. The mean blood glucose level according to
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hearing improvement was 200.8 mg/dl for group A and
181.8 mg/dl for group B, and the difference was not sta-
tistically significant (p = 0.286) (Fig. 3).
Discussion
The etiology of sudden deafness is still not clearly known.
Viral infection and disorders in blood circulation are
thought to be major reasons, but cochlear membrane
rupture, immunodeficiency disease, acoustic tumor, and
head trauma can also cause sudden deafness. The associ-
ation with viral infection has been gleaned from some cases
that were serologically positive, but the exact pathophysi-
ological route or viral infection process remains unclear
[3]. Also, since the cochlea is supplied by the labyrinthine
artery, which has no collateral circulation, vessel obstruc-
tion by thrombosis may cause sudden deafness that cannot
be identified apparently [4]. Diabetes, hyperlipidemia, and
Fig. 1 Comparison of initial
and final (1 month) pure tone
average between diabetes and
non-diabetes group
Table 1 Comparative data
regarding diabetes and non-
diabetes group
Diabetes group (n = 57) Non-diabetes group (n = 140)
Age (years) 57.4 ± 13.9 46.8 ± 15.8
Sex (M:F) 34:23 63:77
Hearing recovery (%) 37 (64.9) 76 (54.3)
Initial audio (dB) 72.1 ± 22.9 60.3 ± 26.8
Final audio (dB) 47.3 ± 23.1 41.2 ± 25.1
Improvement value (dB) 24.8 ± 18.7 19.2 ± 22.6
Fig. 2 Comparison of hearing improvement in pure tone average
between non-glucose level control group (Group I) and glucose
control group (Group II)
Fig. 3 Comparison of mean blood glucose level between patients
with hearing gain greater than 20 dB (Group A) and patients with
hearing gain less than 20 dB (Group B)
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old age are well-known factors of microvessel disease, and
these factors also support the theory of disorder in blood
circulation [5].
Systemic steroid administration is the most popular
treatment method for sudden deafness of unknown origin.
High dose steroid therapy enables anti-inflammatory,
immunosuppressive, and regulatory effects in vessel per-
meability. The therapy can prevent edema in the inner ear
and also suppresses fibrogenesis or scar tissue formation,
which aids in the recovery process by reducing damage in
the inner ear caused by viral infection. Steroids are
involved in the immunosuppression process by reducing
the expression of nuclear factor-kappa beta (NF-jB), a
transcription factor in the immune system. NF-jB is dis-
tributed inside the cochlea and steroid administration has
been reported to reduce this transcription factor. Steroids
also have a regulatory effect in vessel permeability and are
involved in cochlea blood circulation by controlling
homeostasis in endolymphatic fluid [6].
There is little doubt concerning the effectiveness of
steroids in sudden deafness. However, high dosage therapy
(prednisolone 60 mg) is reportedly linked with complica-
tions, most commonly hyperglycemia. In animal experi-
ments, continuous retention of dexamethasone or a
substance interrupting 11b-HSD2 results in hyperglycemia
and hyperinsulinemia [7]. Since hyperglycemia developing
during steroid therapy may result in poor prognosis, there is
always a dilemma between control of blood glucose level
and steroid use. Currently, intra-tympanic steroid injection
is used to avoid systemic complications. However, the
therapeutic outcome is variable, with reported success rates
of 53 and 72.7% [8, 9]. These results indicate the similarity
of outcome of the intra-tympanic method compared to
traditional systemic steroid therapy. However, if the patient
swallows or talks during the process, the injected medi-
cation may be lost through the Eustachian tube and may not
be sufficiently absorbed through the round window. Also, if
the round window niche is covered by a pseudomembrane,
it may reduce steroid absorption and result in lower treat-
ment effect compared to systemic steroid therapy.
Presently, comparison of the level of hearing improve-
ment between diabetes patients and non-diabetes patients
revealed a greater (but not statistically significant) hearing
improvement in diabetes patients. This result was contrary
to prior reports [2, 5, 10–12] that patients with diabetes
have a poor prognosis. Also, a formulation in which
prostaglandin E1 is enclosed in a lipid capsule reportedly
has no statistically significant treatment effect in sudden
deafness [13, 14], but this may be because microvessel
disease does not easily develop in the labyrinthine artery
compared to other vessels. However, the study was limited
by the relatively small number of total patients and because
final pure tone audiometry was performed 1 month after
initial treatment, which may have resulted in a lack of
statistical difference.
Sudden deafness in patients with diabetes has been
linked with more severe hearing loss and poor prognosis
[10, 11]. Also, the post-prandial glucose level and control
of blood glucose level likely affect the course of disease
[10]. However, no study has reported the impact of
hyperglycemic control in the prognosis of sudden deafness
in patients undergoing high dose steroid therapy. Presently,
we compared the level of hearing improvement and mean
blood glucose levels between two groups in which there
was no statistical difference. This conclusion was evaluated
in two ways. First, diabetic patients were divided into two
groups, in which one group showed high glucose levels and
the other group showed normal blood glucose levels.
Results showed that there was no statistical difference in
hearing improvement between the two groups. Second, the
diabetic patients were again categorized, in which one
group showed hearing improvement[20 dB and the other
group showed hearing improvement\20 dB. Again, there
was no statistical difference in mean blood glucose levels
between the two groups. Hence, from these studies, we
were able to conclude that even though sudden deafness
associated with diabetes is known to have a poor prognosis,
our study showed that there was no correlation between the
two diseases.
Also, there were some patients who complained of
headaches and mild edema of the limbs, but there were no
patients who developed severe symptoms such as hyper-
glycemic hyperosmolar nonketotic syndrome. All patients
were well controlled with conservative treatment. There-
fore, all patients received the 10-day regimen treatment
without interruption and this was probably due to the fre-
quent glucose stick test and the swift intervention for
glucose level control using insulin injection.
A change in blood glucose level developing during
systemic therapy in sudden deafness patients is a normal
response and may be worsened in patients with diabetes.
However, this has no direct effect on the prognosis of
sudden deafness; so there should be no restrictions to
systemic steroid therapy due to hyperglycemia.
Conclusion
There is still no clear reason for the etiology of sudden
deafness, but steroid therapy is currently the most popular
treatment method. Sudden deafness in diabetic patients has
been associated with poor prognosis in prior studies, but
not in the present study. This may be due to other factors
causing sudden deafness other than disorders in blood
circulation. Also, since hyperglycemia is the most common
complication of steroid treatment, a balance between
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steroid usage and hyperglycemia in patients with diabetes
is difficult. Blood glucose level needs to be controlled,
since hyperglycemia may cause many complications
including tissue damage of the endocrine system. However,
systemic steroid therapy should be administered without
restrictions since control of blood glucose level during
treatment do not have a direct effect on the prognosis of
sudden deafness.
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